Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 1
2004 3
2005 3
2006 3
2007 1
2010 3
2011 2
2015 2
2016 1
2017 1
2018 1
2019 1
2021 1
2022 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Deferiprone in Parkinson's Disease.
Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Růžička E, Dušek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garçon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group. Devos D, et al. Among authors: fradette c. N Engl J Med. 2022 Dec 1;387(22):2045-2055. doi: 10.1056/NEJMoa2209254. N Engl J Med. 2022. PMID: 36449420 Clinical Trial.
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.
Elalfy MS, Hamdy M, El-Beshlawy A, Ebeid FSE, Badr M, Kanter J, Inusa B, Adly AAM, Williams S, Kilinc Y, Lee D, Fradette C, Rozova A, Temin NT, Tricta F, Kwiatkowski JL. Elalfy MS, et al. Among authors: fradette c. Blood Adv. 2023 Feb 28;7(4):611-619. doi: 10.1182/bloodadvances.2021006778. Blood Adv. 2023. PMID: 36018224 Free PMC article. Clinical Trial.
Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START).
Elalfy MS, Hamdy M, Adly A, Ebeid FSE, Temin NT, Rozova A, Lee D, Fradette C, Tricta F. Elalfy MS, et al. Among authors: fradette c. Am J Hematol. 2023 Sep;98(9):1415-1424. doi: 10.1002/ajh.27010. Epub 2023 Jul 4. Am J Hematol. 2023. PMID: 37401738 Clinical Trial.
Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Hamdy M, El-Beshlawy A, Veríssimo MPA, Kanter J, Inusa B, Williams S, Lee D, Temin NT, Fradette C, Tricta F, Ebeid FSE, Kwiatkowski JL, Elalfy MS. Hamdy M, et al. Among authors: fradette c. Pediatr Blood Cancer. 2024 Jan;71(1):e30711. doi: 10.1002/pbc.30711. Epub 2023 Oct 9. Pediatr Blood Cancer. 2024. PMID: 37807937 Clinical Trial.
The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study.
Badawy SM, Kattamis A, Ezzat H, Deschamps B, Sicard E, Fradette C, Zhao F, Tricta F, Chung Tsang Y, Sheth S, Piga A. Badawy SM, et al. Among authors: fradette c. Br J Haematol. 2022 Apr;197(1):e12-e15. doi: 10.1111/bjh.17999. Epub 2021 Dec 21. Br J Haematol. 2022. PMID: 34931307 Free PMC article. Clinical Trial. No abstract available.
28 results